Argininosuccinate lyase deficiency, also called argininosuccinic aciduria, is a urea cycle disorder caused by biallelic pathogenic variants in the ASL gene. It is inherited in an autosomal recessive manner and reduces the conversion of argininosuccinate to arginine and fumarate. The block causes accumulation of argininosuccinate, arginine deficiency, and insufficient nitrogen elimination, with risk of hyperammonemia and systemic involvement.
Argininosuccinate lyase deficiency
The ASL gene encodes an essential cytosolic enzyme of the urea cycle. In the liver, it allows for the continued transformation of toxic nitrogen into urea for renal excretion. In other tissues, it participates in the synthesis of arginine from citrulline and in the production of nitric oxide, important for vascular and neuronal function.
Pathogenic variants decrease or abolish enzymatic activity, leading to the accumulation of argininosuccinate and citrulline, and a decrease in tissue arginine availability. Alteration of nitric oxide may contribute to hypertension and neurocognitive complications. Prevalence is estimated between 1 in 70,000 and 218,000 births, although it may be underdiagnosed. Founder effects have been described in Saudi Arabia, Druze communities, and Finland.
Symptoms
Severe neonatal form usually begins in the first days of life with feeding refusal, vomiting, lethargy, rapid breathing, and respiratory alkalosis. Without treatment, hyperammonemia can progress to seizures, cerebral edema, coma, and death. Late forms may manifest in infancy or adulthood through crises triggered by infections, fasting, surgery, or other catabolic situations. Developmental delay, learning difficulties, behavioral disorders, attention deficit, epilepsy, hypotonia, tremor, or ataxia may also appear, even without documented hyperammonemia. Hepatomegaly and elevated transaminases are frequent; some patients develop fibrosis or cirrhosis. Other findings include brittle hair from trichorrhexis nodosa, hypertension, and hypokalemia. Severity is highly variable.
Disease management
There is currently no curative treatment. Management includes individualized protein restriction, sufficient energy intake to avoid catabolism, essential amino acid supplements when necessary, and arginine administration. Nitrogen-scavenging drugs are used if recurrent hyperammonemia or insufficient metabolic control exists. Excessive protein restriction can also be detrimental, so the diet requires specialized supervision.
Acute decompensations are medical emergencies and require temporary suspension of proteins, intravenous glucose and lipids, nitrogen scavengers, and, in severe cases, hemodialysis or hemofiltration. Follow-up includes plasma ammonia and amino acids, nutritional status, neurological development, liver function, fibrosis, and blood pressure. Liver transplantation can prevent new crises in selected patients, but it does not guarantee reversal of neurological or extrahepatic involvement. Strategies targeting nitric oxide and gene therapies remain under investigation.
Genes analyzed
Bibliography
Nagamani SCS, Burrage LC, Lee B. Argininosuccinate Lyase Deficiency. GeneReviews®. 2011; updated 2025.
Häberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision. J Inherit Metab Dis. 2019;42(6):1192-1230.
Baruteau J, Diez-Fernandez C, Lerner S, et al. Argininosuccinic aciduria: Recent pathophysiological insights and therapeutic prospects. J Inherit Metab Dis. 2019;42(6):1147-1161.
